Publicacións en colaboración con investigadores/as de Mayo Clinic (19)

2024

  1. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2023

  1. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  2. Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance

    Arthritis Care and Research, Vol. 75, Núm. 1, pp. 53-60

  3. Measurement Properties of Outcome Instruments for Large-Vessel Vasculitis: A Systematic Literature Review

    The Journal of rheumatology, Vol. 50, Núm. 6, pp. 789-798

2022

  1. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry

    ACR Open Rheumatology, Vol. 4, Núm. 11, pp. 948-953

  2. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

    Annals of the rheumatic diseases, Vol. 81, Núm. 7, pp. 970-978

  3. Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry

    ACR Open Rheumatology, Vol. 4, Núm. 10, pp. 872-882

  4. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

    The Lancet Rheumatology, Vol. 4, Núm. 9, pp. e603-e613

  5. Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4603-4618

2021

  1. Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19

    JAMA Network Open

  2. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 9, pp. 1137-1146

  3. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

    The Lancet Rheumatology, Vol. 3, Núm. 12, pp. e855-e864

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

2015

  1. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility

    American Journal of Human Genetics, Vol. 96, Núm. 4, pp. 565-580

2014

  1. The global burden of rheumatoid arthritis: Estimates from the Global Burden of Disease 2010 study

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 7, pp. 1316-1322

2012

  1. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  2. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196

2004

  1. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: A population-based study

    Medicine, Vol. 83, Núm. 6, pp. 335-341

2000

  1. Cutaneous vasculitis and cancer: A clinical approach

    Clinical and Experimental Rheumatology